Inhoudsopgave:
|
\u003cp\u003e\u003ci\u003eAnticandidal Agents \u003c/i\u003eprovides the latest information on candida drug resistance and its remedial implications. In this compilation, users will find a comprehensive view on overcoming resistance in anticandidal drugs, along with information on novel molecules. \u003c/p\u003e \u003cp\u003eCandida albicans is an opportunistic pathogenic fungus responsible for life threating invasive and nosocomial infections across the globe. Candidiasis is a major cause of morbidity among immunocompromised patients. Infections caused by non-albicans candida like C. glabrata, C. parapsilosis, and C. tropicalis have also imposed a serious threat in the last few decades. Current treatment of candidiasis relies primarily on antifungal agents broadly categorized as azoles, polyenes, echinocandins, allylamines, and pyrimidines. \u003c/p\u003e \u003cp\u003eLately, antifungal resistance has emerged to be an obstruction of current treatment regime. A number of reasons are described in detail. Understanding the mechanisms of resistance is crucial for developing strategies for overcoming the hindrance in current therapeutics.\u003c/p\u003e\u003cul\u003e \u003cli\u003ePresents a complete understanding of candida resistance to help in the development of therapeutic expansion and novel drugs\u003c/li\u003e \u003cli\u003eProvides thorough information on candida drug resistance and its remedial implications\u003c/li\u003e \u003cli\u003eCovers crucial mechanisms of resistance that will help develop strategies for overcoming the hindrance in current therapeutics\u003c/li\u003e\u003c/ul\u003e |
nl
en